Chief Executive Officer
Mon, Dec 19, 2022
Dec 19
exercised or converted securities in APLS
15,000 shares @ $0.00
Decreased holdings by -5.50%
Net across this filing: +1.00% (+9,188 shares)
Option Exercise
Sale tied to a same-time option exercise
Win rate excludes trades classified as routine (tax, 10b5-1, exercise, gift).
APLSApellis Pharmaceuticals, Inc.
HealthcareBiotechnology